What it does
Formed in 1997 as an investment syndicate, it now specialises in four areas – equity financing, debt financing, advisory services and fund management.
Braveheart invests in businesses through its many funds including the Finance Yorkshire Equity Fund, Strathclyde Innovation Fund and Lachesis Seed Fund.
The group, which floated on the London Stock Exchange in 2007, also invests on behalf of high net worth individuals, family offices, institutional investors and public sector organisations across the UK and Europe.
What it owns
Braveheart now holds six strategic investments in its portfolio alongside other historical investments.
These included biotechnology firm Kirkstall, UV light detection group Paraytec, propeller and rotating shaft monitoring group Gyrometric Systems, microscope imaging firm PhaseFocus and Sentinel Medical, a spin-out of Paraytec developing technology to detect cancer cells in urine.
On 8 July, the company said that it had also acquired a 33% stake in Pharm2Farm Limited (P2F), a plant nutrients firm, a stake it wants to increase to 54%.
In September, P2F announced a good result from a trial with Korean firm with a significant improvement in taste and the rate of growth of basil using its technology
How it's doing
In a November update, Braveheart said it expects Paraytec (100%) to start the second round of user trials early in 2020.
Paraytec is part of an Innovate UK funded R&D project (NEXUS) that includes Malvern Panalytical, the University of Central Lancashire, GSK, Medimmune and Fujifilm Diosynth.
Aggregates are an impurity that must be controlled and must stay within product specifications, so measurement is essential to ensure they meet the requirements of regulatory agencies.
Plant nutrients firm Pharm 2 Farm (Braveheart 33.33%) is bidding to get some of the £90mln Innovate UK grant funding available to help agritech businesses.
Biotechnology company Kirkstall (64.67%) is involved with the €4.7 million Horizon 2020 project developing techniques to grow human organs by using light to modify the growth of cells.
Kirkstall is providing specialist Quasi-Vivo products in which the cell cultures will be grown.
Gyrometric Systems (19.95%) has developed shaft monitoring and measurement systems for revolutions as low as 0.25 revolutions per minute, which is useful for wind turbines.
Its ship drive monitoring systems, meanwhile, will be exhibited next year in September at SMM Hamburg, the world's largest exhibition for ship technology.
Phasefocus Holdings (21.20%) has recently been granted a new US patent for a fundamental improvement in its underlying ptychography imaging technology.
The method protected by the new patent has the potential to speed up Phasefocus's systems by a factor of 10 times.
Sentinel Medical (38.40%) is to revise the trial protocols for its prototype instrument to detect bladder cancer from urine after initial work at Sheffield University.
In the first half of the current financial year, Braveheart made a profit before tax of £113,000 on revenue of £509,000.
Net assets were worth 8.42p per share or £2.28mln.
What the boss says: Trevor Brown
"For the next year, our attention and resources will continue to be focussed upon the further development of the now six strategic Investment businesses where we have significant commercial exposure.
In each of these businesses there exists the prospect of a single transformational event, for example securing a large sales contract with a major OEM, the development of a new product or application and an outright sale to an acquirer."
Watch the video
New round of user trials for Paraytec
Commercial orders for Gyrometric